Nagoya City University Academic Repository
学 位 の 種 類 博士 (医学) 報 告 番 号 甲第１７４１号 学 位 記 番 号 第１２３８号 氏 名 竹内 章 授 与 年 月 日 令和 2 年 3 月 25 日 学位論文の題名
TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer
(非扁平上皮非小細胞肺癌において TTF-1 発現は血管新生阻害剤の併用効 果を予測する)
Anticancer Res, 38: 5489-5495, 2018
論文審査担当者 主査： 中西 良一
Anticancer Res. 2018 Sep;38(9):5489-5495
Title: TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer.
Authors: Takeuchi A, Oguri T, Yamashita Y, Sone K, Fukuda S, Takakuwa O, Uemura T, Maeno K, Fukumitsu K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A.
Abstract;
Addition of antiangiogenic agent, bevacizumab, to platinum drug combined therapy is one of the standard chemotherapeutic regimens for advanced non-squamous non-small cell lung cancer (NS-NSCLC). However, a predictive marker of the effectiveness of bevacizumab is not established. Recently, thyroid transcription factor 1 (TTF-1), which is used as a diagnostic marker for lung adenocarcinoma in clinical practice, was shown to reprogram angiogenic activities through the proangiogenic factor. To investigate whether TTF-1 expression predicts a beneficial response of non-squamous non-small-cell lung cancer (NS-NSCLC) patients to bevacizumab, we retrospectively screened 118 advanced NS-NSCLC patients who were treated with pemetrexed plus platinum derivatives alone (Bev(-)) or with bevacizumab (Bev(+)). We investigated the relationship between expression of TTF-1 and treatment outcomes. Among the 92 TTF-1-positive patients, clinical outcomes in the Bev(+) group were significantly better than those in the Bev(-) group (response rate, 51.4% vs. 27.3%, p=0.027; median progression-free survival, 216 days vs. 137 days, p=0.012). Overall survival in the Bev(+) group tended to be longer than that in the Bev(-) group. However, the addition of bevacizumab to the standard treatment of 26 TTF-1-negative patients offered no clinical benefit. TTF-1 expression may serve as a predictive marker to identify patients who may benefit from the addition of bevacizumab to platinum doublet therapy.
